Autopsy report · NCT00360828

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

“Principal Investigator left Moffitt and study had low accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months after it had already started.
• Ran for about 4 years 8 months before it stopped.
• 10 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Sponsor type

University, hospital or other

Conditions

Astrocytoma; Glioma; Oligodendroglioma

Interventions

Irinotecan Hydrochloride (HCI) Treatment; Continued Irinotecan Hydrochloride (HCI) Treatment

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
  “The study was terminated due to low accrual.” (73% match in meaning)
• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (71% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (70% match in meaning)
• Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
  “the study had a low accrual rate” (70% match in meaning)
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.